Impact of Tamsulosin OCAS on Energy of Patients with LUTS/BPH Mark Speakman  European Urology Supplements  Volume 6, Issue 9, Pages 594-599 (April 2007) DOI: 10.1016/j.eursup.2007.01.003 Copyright © 2007 European Association of Urology Terms and Conditions

Fig. 1 (A) The pharmacokinetic (PK) profile of tamsulosin oral controlled absorption system (OCAS) 0.4mg shows a reduced Cmax and a consistent and continued 24-h plasma concentration of tamsulosin (mean PK profile of eight subjects). (B) Scintigraphic analysis shows that tamsulosin is released from the OCAS tablet throughout the entire gastrointestinal tract, including the colon. Reprinted from Stevens et al [30], with permission from Librapharm Limited. European Urology Supplements 2007 6, 594-599DOI: (10.1016/j.eursup.2007.01.003) Copyright © 2007 European Association of Urology Terms and Conditions

Fig. 2 The relationship between behaviour of tamsulosin oral controlled absorption system in the gastrointestinal tract (GI) and its impact on quality of sleep and quality of life. *Not significant versus placebo. HUS=hours of undisturbed sleep. European Urology Supplements 2007 6, 594-599DOI: (10.1016/j.eursup.2007.01.003) Copyright © 2007 European Association of Urology Terms and Conditions